Stryker Corporation (SYK)

Stryker's Q3 2025 earnings, announced on October 30, 2025, reported a 10.2% year-over-year sales growth to $6.06 billion and adjusted EPS of $3.19, surpassing analyst estimates. During its Q2 2025 earnings call on July 31, 2025, Stryker reported 10.2% organic sales growth and 11.4% adjusted EPS growth and raised its full-year 2025 guidance. On July 31, 2025, Stryker received FDA 510(k) Clearance for its OptaBlate System. The acquisition of Inari Medical, announced on May 1, 2025, has been integrated, bolstering Stryker's product portfolio. On May 19, 2025, Stryker lowered its adjusted EPS view due to an anticipated $200 million tariff impact. Stryker declared a quarterly dividend of $0.88 per share on December 11, 2025. The stock experienced fluctuations, hitting a 4-week high of $361.14 on January 6, 2026, and a 36-week low of $347.23 on January 2, 2026. Insiders sold approximately 522,118 shares, valued at about $185.38 million, in the three months leading up to January 6, 2026. Analysts have updated their ratings and price targets for SYK, with a consensus of "Moderate Buy" and an average 12-month price target of approximately $430.00.

The demand for Stryker Corp.'s products and services is generally stable and not highly dependent on the overall economy, as surgical procedures and emergency medical attention are consistently required. While the broader Healthcare sector exhibits seasonal strength from April 25 to December 4, this primarily relates to market trends rather than direct seasonality in the demand for Stryker's medical devices and services. The company's consistent revenue growth and the nature of its essential medical products suggest relatively steady demand throughout the year.

Stryker Corp. is a global medical technology company in the Healthcare sector, specifically the Medical Devices industry. It designs, manufactures, and markets products and services across Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment includes implants for joint replacements, trauma and extremities surgeries, and reconstructive implant systems. The MedSurg segment offers surgical equipment, navigation systems, endoscopic and communications systems, patient handling equipment, emergency medical equipment, intensive care disposable products, and reprocessed medical devices. The Neurotechnology and Spine segment provides neurosurgical and neurovascular devices, spinal implant systems, dural substitutes and sealants, and products for brain and skull-based surgical procedures.

Stryker Corp. operates in over 100 countries and is segmented into four regions: the United States, Europe (including the Middle East and Africa), Asia Pacific, and other countries. Stryker sells its products through subsidiaries, branches, third-party dealers, and distributors across the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Within the past year, specific events that significantly impacted Stryker Corp.'s brand reputation were not prominently detailed in the search results. The company has faced "Ongoing Legal and Regulatory Matters," including product liability claims and investigations into potential FCPA violations, mentioned as a general weakness in October 2025. Historically, Stryker has dealt with lawsuits and recalls related to hip implants and criminal charges, but these events predate the past year.

Stryker Corp. has a diverse ownership structure, with approximately 61.68% of the company's stock owned by Institutional Investors, 4.38% by Insiders, and 33.95% by Public Companies and Individual Investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Greenleaf Trust, State Street Corp, Jpmorgan Chase & Co, Price T Rowe Associates Inc /md/, Geode Capital Management, Llc, Morgan Stanley, AllianceBernstein L.P., Capital Research Global Investors, Wellington Management Group LLP, and Fidelity Management & Research. Notable individual insider ownership includes John W. Brown, and Director Ronda Stryker has also engaged in significant stock sales in recent months.